On Aug. 24, 2020, Innovation Pharma reported receiving additional data from a U.S. Regional Biocontainment Laboratory (RBL) based on ongoing in vitro testing supporting Brilacidin as a potential treatment for SARS-CoV-2, the novel coronavirus responsible for COVID-19.

Brilacidin exhibited robust in vitro anti-SARS-CoV-2 efficacy at low concentrations, well below already established clinically-achievable concentrations based on pharmacokinetics observed in the Companyﾒs Phase 2b clinical trial of Brilacidin in Acute Bacterial Skin and Skin Structure Infections.